* United Therapeutics Corp reported quarterly adjusted earnings of $6.39 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $5.38. The mean expectation of thirteen analysts for the quarter was for earnings of $6.42 per share. Wall Street expected results to range from $5.41 to $7.41 per share.
* Revenue rose 22.9% to $748.90 million from a year ago; analysts expected $722.58 million.
* United Therapeutics Corp's reported EPS for the quarter was $6.39.
* The company reported quarterly net income of $309.1 million.
* United Therapeutics Corp shares had fallen by 1.5% this quarter and gained 60.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for United Therapeutics Corp is $382.06 This summary was machine generated from LSEG data October 30 at 03:11 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 6.42 6.39 Missed
Jun. 30 2024 6.40 5.85 Missed
Mar. 31 2024 5.65 6.17 Beat
Dec. 31 2023 4.19 4.36 Beat
Comments